Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DONIMI: Domatinostat Combinations in Stage III Melanoma
NCT04133948Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of Domatinostat in cutaneous melanoma (CM) (4 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety of patients as measured by the adherence to the timelines in the study protocol at 6 months and Feasability of patients as measured by the adherence to the timelines in the study protocol at 6 weeks. Started Jan 2020; status: completed.
02
Drugs
Domatinostat
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT04133948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04133948.